Business Wire

CURRENCYFAIR

12.6.2019 10:32:08 CEST | Business Wire | Press release

Share
The Brexit Breakup: CurrencyFair Survey Reveals 34% of British Expats Are Currently Seeking Citizenship or Permanent Residency in Another Country Due to Brexit

More than a third of British expats (34 percent) are already actively seeking a formal farewell to their home country due Brexit, and a further 5 percent will seek citizenship for themselves and/or their family in case of a hard Brexit, according to a survey commissioned by international money transfer service CurrencyFair.

The survey, concluding in May, compared British expats’ preferred Brexit outcomes and plans for Brexit with the views of British citizens residing at home. Expats living in EU countries that are expected to be most significantly impacted by Brexit were surveyed, including Germany, France, the Netherlands and Ireland.

Voting with their passports

Over half of the British citizens living outside of the UK surveyed are worried about their citizenship rights as an expat (53 percent), and half (50 percent) are concerned about their citizenship rights in commonwealth countries due to Brexit, which may be a trigger for the rush to seek a citizenship berth outside of their birth country.

"Expats tend to be at the leading edge of the intersection between personal finance and current events, and their behaviour is a barometer for bigger trends and changes,” said Paul Byrne, CEO of CurrencyFair. “Our research indicates that Brexit may be forcing the hand of expats to seek citizenship they might not otherwise seek, as they search for viable options in the event of a hard Brexit and any negative economic consequences.”

Bracing for a recession

In addition to alternative citizenship, a quarter of British expats surveyed say they plan to brace for a recession in the event of a hard Brexit, and plan to liquidate UK assets (17 percent) or transfer money abroad (13 percent) if the UK crashes out of the EU without a deal. A third of expats noted that when choosing a provider to transfer money to and from the UK, transparency about fees charged ranks first as the most important aspect, tied with security and trust in service provider.

“People are hearing our message that paying marked up exchange rates and hidden fees for currency exchange isn’t sustainable for expats from a personal finance perspective,” Byrne said

Overall, expats are more worried than UK residents about the uncertainty surrounding the UK’s departure from the EU, from the amount of debt they currently have (42 percent for expats versus 20 percent for UK residents), to the impact of Brexit on their retirement (52 percent expats versus 34 percent in the UK), and their ability to buy the things they want (52 percent expats versus 41 percent in the UK).

This worry is translating into immediate action for many expats who revealed they are already focusing on paying off any unsecured debt (16 percent versus 12 percent in the UK), moving investments to lower risk funds (14 percent versus five percent in the UK), and changing retirement plans (14 percent versus two percent in the UK).

The survey revealed that UK citizens residing at home have a certain confidence when it comes to their own finances. While 54 percent are concerned that the UK economic situation will worsen over the next 12 months, the same percentage believe their individual economic situation will either stay the same or improve. Additionally, the majority of UK residents (54 percent) indicate they plan to do nothing if there is a no-deal Brexit beyond bracing for a recession (42 percent).

“The survey suggests that expats and UK citizens residing at home have contrasting views when it comes to how they anticipate Brexit will affect their lives. It’s clear that when it comes to Brexit, where one stands on the issues depends on where one sits in the world,” said Byrne.

The Irish question

In the Brexit blame game, the Irish government gets off scot-free. Only four percent of British expats surveyed hold the Irish government responsible, despite assertions in some media quarters that the Irish government has ‘overplayed its hand’ on Brexit. A full twenty-seven percent of British expats in Ireland, however, blame the mainstream media or ‘fake news’ for the state of Brexit negotiations. Interestingly, British expats living in Ireland are significantly more likely than others to blame the British public for the current state of affairs. Twenty-seven percent say the British public is at fault, compared to just 16 percent of expats in other countries that blame their fellow countrymen.

Leadership vacuum

The likes of British prime ministers Theresa May and David Cameron, however, take the lion’s share of blame for the current state of Brexit negotiations. Both UK citizens residing at home and expats struggled to suggest an appropriate alternative, with only one in 10 expats choosing Michael Gove, and one in 10 UK citizens residing at home choosing Boris Johnson. When asked which notable person - living or dead - would have Brexit sorted by now if they were in charge, 32 percent of UK nationals said former prime minister Margaret Thatcher and 24 percent said they felt former prime minister Winston Churchill would get the job done. Expats living in France and Germany felt leaders in their adoptive countries, president Emmanuel Macron and chancellor Angela Merkel, respectively, would do a better job handling Brexit. Kylie Minogue ranked second in both Germany and The Netherlands with 15 percent and 18 percent respectively choosing the singer. Twelve percent of expats surveyed in the Netherlands chose Meghan, Duchess of Sussex, formerly known as Meghan Markle.

All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 664 adults. Fieldwork was undertaken between 18th April - 2nd May 2019. The survey was carried out online. The figures have been weighted and are representative of all GB adults (aged 18+).

-30-

CurrencyFair is an international money transfer platform focused on providing the best available exchange rates and experience for customers who need to send money and make payments overseas. CurrencyFair’s 150,000 strong user-community have traded more than €8 billion and saved more than €205 million using the service. Our unique peer-to-peer model and secure, state-of-the-art technology, raises the industry standard in designing technology-led foreign currency services for web, IOS and Android use. The company has offices in Ireland, Singapore, Hong Kong and Australia, and announced plans to expand further across Asia in 2019 after acquiring Convoy Payments (Hong Kong) in December 2018.

…

Contact:

Killeen Kelly killeenkelly@currencyfair.com +353 87 380 6879

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye